ESMO 2024 | DESTINY-Breast12: enhancing outcomes for HR+/HER2+ patients with brain metastases

Eva Ciruelos • 15 Sep 2024

ESMO 2024

DESTINY-Breast12

Eva Ciruelos, MD, PhD, Hospital 12 de Octubre, Madrid, Spain, shares insights from the Phase II DESTINY-Breast12 trial (NCT04739761), involving 500 patients with HER2-positive, hormone receptor-positive (HR+/HER2+) breast cancer. Notably, 50% of patients in the trial had brain metastases, either stable or active. In patients with brain metastases, trastuzumab deruxtecan (T-DXd) achieved an overall response rate (ORR) and median progression-free survival (PFS) similar to those without brain metastases. This reinforces T-DXd as the preferred second-line treatment for HER2+ breast cancer, regardless of brain metastasis status. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.